[Research Report] The angioplasty balloons market is projected to grow from US$ 2.71 billion in 2022 to US$ 3.60 billion by 2030, recording a CAGR of 3.6% from 2022 to 2030.

Market Insights and Analyst View:

The angioplasty balloons market forecast can help stakeholders in this marketplace plan their growth strategies. The report includes growth prospects, along with the angioplasty balloons market trends and their foreseeable impact during the forecast period.

An angioplasty is a technique used to widen narrowed or open clogged coronary arteries and restore blood flow. Value-based care, which focuses on cost-effectiveness and patient outcomes, is changing the healthcare sector. The market for angioplasty balloons will be influenced by the capacity of these devices to provide better patient outcomes, reduced rates of revascularization, and lower costs as compared to other available treatments. Compared to conventional surgical methods, angioplasty balloons provide a less invasive method of treating clogged arteries. The need for angioplasty balloons is rising as patients and medical professionals show a greater preference for less invasive procedures. The rising prevalence of cardiovascular diseases and increasing preference for minimally invasive procedures contribute to the growing angioplasty balloons market size. However, complications associated with angioplasty impede the growth of the market.

Growth Drivers:

Increasing Prevalence of Cardiovascular Diseases Drives Angioplasty Balloons Market

According to the World Health Organization (WHO), cardiovascular diseases are the most prominent cause of morbidity and mortality worldwide. Cardiovascular diseases include cerebrovascular disease, coronary heart disease, and rheumatic heart disease. Major lifestyle factors causing cardiovascular diseases and related difficulties are tobacco consumption, unhealthy diet, and physical inactivity, among others. According to the American Heart Association Inc., the cardiovascular disease-related deaths recorded in 2020 increased to 928,741 from 874,613 in 2019. In 2020, coronary heart disease was the leading cause (41.2%) of deaths attributable to cardiovascular diseases in the US, followed by stroke (17.3%), high blood pressure (12.9%), heart failure (9.2%), diseases of the arteries (2.6%), and other cardiovascular diseases (16.8%). Also, the World Heart Federation predicts more than 23 million cardiovascular disease-related deaths per year by 2030.

Moreover, cardiovascular risk factors are highly prevalent in Central and Western Europe, owing to smoking habits and heavy alcohol consumption rates, especially among men. More than 4 million Europeans die yearly from cardiovascular diseases, mainly due to coronary artery disease and stroke. The Middle East also has a high prevalence rate of cardiovascular diseases, which has surged the need for various interventions such as health education, lifestyle counseling, screening, and treatment in this region. According to the World Heart Federation, cardiovascular disease is the primary cause of death in the Middle East & North Africa, accounting for more than a third of all deaths or 1.4 million people annually. Thus, the increasing prevalence of cardiovascular diseases propels the angioplasty balloons market growth.

Angioplasty operations are considered by most to be safe, but there have been reported cases of problems developing during or age the surgery. A blood clot, irregular heartbeat, damage to a blood vessel or heart valve, stroke, allergic response to the stent material or drug-eluting stent, in-stent restenosis, or clogging of the stent's interior are a few of the risks involved in theangioplasty operations. While some of these risks are extremely dangerous, others might even be fatal. Furthermore, the patient might not have enough time in some circumstances to have an angioplasty. This typically occurs in the event of a heart attack. All of these problems hinder the angioplasty balloons market growth.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Angioplasty Balloons Market: Strategic Insights

Market Size Value in	US$ 2.71 billion in 2022
Market Size Value by	US$ 3.60 billion by 2030
Growth rate	CAGR of 3.6% from 2022 to 2030
Forecast Period	2022-2030
Base Year	2022

Mrinal

Have a question?

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Report Segmentation and Scope:

The angioplasty balloons market analysis has been carried out by considering the following segments: type, application, and end user.

Segmental Analysis:

By type, the angioplasty balloons market is segmented into normal balloons, drug eluting balloons, cutting balloons, and scoring balloons. The normal balloons segment held the largest market share in 2022. However, the drug eluting balloons segment is anticipated to register the highest CAGR during 2022–2030. 

By application, the angioplasty balloons market is bifurcated into peripheral and coronary. The coronary segment held a larger angioplasty balloons market share in 2022 and is anticipated to register the highest CAGR during 2022–2030 due to the increasing prevalence of coronary artery diseases, especially heart disease. As per the March 2023 update from the Centers for Disease Control and Prevention (CDC), coronary heart disease is the most prevalent type of heart disease, affecting approximately 1 in 20 persons aged 20 and above. However, the peripheral segment is anticipated to register a higher CAGR during 2022–2030.

The angioplasty balloons market, based on end user, is segmented into hospitals, ambulatory surgery centers, and cath labs. The hospitals segment held the largest angioplasty balloons market share in 2022 and is anticipated to register the highest CAGR during 2022–2030.

Regional Analysis:

The geographic scope of the angioplasty balloons market report includes North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest market share in 2022. The market growth in North America is driven by the increasing burden of an aging population, rising number of product launches, and R&D activities to develop advanced angioplasty balloons.

Angioplasty Balloons Market Report Scope

Competitive Landscape and Key Companies:

Abbott, Boston Scientific Corporation, Cardinal Health, Cook Medical, C. R. Bard Inc, ENDOCOR GmbH, Medtronic, Spectranetics, BIOTRONIK, and Terumo Medical Corporation are among the prominent companies profiled in the angioplasty balloons market report. These companies focus on developing new technologies, upgrading existing products, and expanding their geographic presence to meet the growing consumer demand worldwide. As per company press releases, below are a few recent key developments:

• In March 2023, in the US, SIS Medical AG introduced the OPN NC PTCA Dilatation Catheter with TWIN-Wall technology. By offering great performance and safety along with success rates where other balloons fail, the product expands therapy possibilities. The OPN NC catheter features a TWIN-Wall design, which offers a super-high pressure resistance with a rated burst pressure of 35 atm with a significantly low compliance.
• In September 2022, the FDA granted Advanced NanoTherapies a Breakthrough Device Designation (BDD) for its SirPlux Duo Drug-Coated Balloon (DCB) to treat coronary artery disease. SirPlux Duo DCB delivers low-dose, long-term release of both compounds to inhibit cell growth, resulting in maximum potency exceeding any other DCB or drug-eluting stent.
• In January 2022, The Scoreflex NC Scoring PTCA Catheter received Premarket Approval (PMA) from the US Food and Drug Administration (FDA). The Scoreflex NC is a scoring PTCA catheter indicated for the de novo stenotic portion of a coronary artery and in-stent restenosis in coronary arteries in patients evident with coronary ischemia for the purpose of improving myocardial perfusion.